drugset
drugset / Trial / NCT00588991

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

NCT00588991 ↗

Phase 1 Completed 12 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of veliparib when given together with topotecan hydrochloride with or without carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with topotecan hydrochloride and carboplatin may kill more cancer cells.

Timeline

Start
2008-02-04
Primary completion
2016-11-01
Completion
2016-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Veliparib Small molecule — Oral
Background Topotecan Small molecule — Intravenous

Indications

acquired polycythemia vera acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with minimal differentiation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myeloid leukemia, t(8;21)(q22; q22.1) acute myeloid leukemia, t(9;11)(p21.3;q23.3) acute myelomonocytic leukemia M4 adult acute lymphoblastic leukemia adult acute monocytic leukemia chronic myeloid leukemia chronic myelomonocytic leukemia erythroleukemia essential thrombocythemia myelodysplastic syndrome